Table 3.
Distribution of first-line therapy prescribed in a population-based cohort of patients with hypertension
| Treatment | Patients | Duration of prescription |
|---|---|---|
| (N = 660,545) (%) | (Mean ± SD) [days] | |
| ACE inhibitors | 191,816 (29.0%) | 800.3 ± 1,082.2 |
| Thiazide diuretics | 145,968 (22.1%) | 540.0 ± 928.0 |
| CCBs | 138,703 (21.0%) | 616.6 ± 924.0 |
| Beta-blockers | 87,211 (13.2%) | 581.4 ± 966.9 |
| Loop diuretics | 36,579 (5.5%) | 222.2 ± 510.8 |
| ARBs | 16,779 (2.5%) | 920.5 ± 1,216.3 |
| Central-acting agents | 12,054 (1.8%) | 192.8 ± 453.3 |
| Beta-blockers + thiazide diuretics | 3,976 (0.6%) | 829.4 ± 1,140.2 |
| Alpha-blockers | 3,673 (0.6%) | 458.7 ± 766.2 |
| Loop diuretics + potassium diuretics | 2,681 (0.4%) | 523.4 ± 779.0 |
| ACE inhibitors + thiazide diuretics | 2,671 (0.4%) | 863.1 ± 1,192.8 |
| ACE inhibitors + beta-blockers | 2,556 (0.4%) | 853.4 ± 1,124.0 |
| ACE inhibitors + CCBs | 2,306 (0.3%) | 768.5 ± 1,025.3 |
| Potassium diuretics | 1,951 (0.3%) | 325.1 ± 601.5 |
| CCBs + thiazide diuretics | 1,739 (0.3%) | 777.8 ± 1,150.1 |
| ACE inhibitors + loop diuretics | 1,302 (0.2%) | 574.2 ± 841.7 |
| ARBs + thiazide diuretics | 1,135 (0.2%) | 961.1 ± 1,238.0 |
| Beta-blockers + CCBs | 1,122 (0.2%) | 736.3 ± 1,112.9 |
| Potassium diuretics + thiazide diuretics | 1,093 (0.2%) | 694.7 ± 1,044.2 |
| Others | 5,230 (0.8%) | 695.0 ± 966.5 |
Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium-channel blockers; Thiazide diuretics, thiazide and thiazide-like diuretics.